Inferra AI / Company / CORT
Corcept Therapeutics Inc.
CORT · Health Care
Last earnings Jul 29, 2026
Key results
Net incomequarter
$35.1 million
Net income of $35.1 million, compared to $35.5 million in second quarter 2024 Cash and investments of $515.0 million at June 30, 2025 Acquired $115.4 million of Corcept common stock in second quarter 2025 REDWOOD CITY, Calif.
SEC original ↗Corcept Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Revenuequarter
$194.4 million
Corcept s second quarter 2025 revenue was $194.4 million, compared to $163.8 million in the second quarter of 2024.
SEC original ↗Corcept Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Net income per common share (diluted) was $0.29 in the second quarter of 2025, compared to $0.32 in the second quarter of 2024.
SEC original ↗Corcept Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
AI analysis
Q2 2025 · reported Jul 31, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Net income | $35.1 million | — | — |
| Revenue | $194.4 million | — | $163.8 million |
Guidance · company-stated
No guidance located in the held release
“6 million Increase in 2026 revenue guidance to $1.”
Capital allocation
The balance at June 30, 2025 reflects the acquisition of $115.4 million of common stock in the second quarter pursuant to the company s stock repurchase program, net exercise of employee stock options and net vesting of restricted stock grants.
We periodically review our debt securities to determine if any of our investments is impaired due to the issuer s poor credit or other reasons.
Event summary
Financial Results The second quarter marked another period of robust growth in our hypercortisolism business
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The balance at June 30, 2025 reflects the acquisition of $115.4 million of common stock in the second quarter pursuant to the company s stock repurchase program, net exercise of employee stock options and net vesting of restricted stock grants.
SEC original ↗Corcept Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
We periodically review our debt securities to determine if any of our investments is impaired due to the issuer s poor credit or other reasons.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
As the operating leases for our facilities do not provide sufficient information to determine the implicit borrowing rate, we calculated the present value of remaining lease payments using a discount rate equal to the interest rate we would pay on a collateralized loan with monthly payments and a term equal to the remaining term of our lease.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
Net Income Per Share We compute our basic and diluted net income per share in conformity with the two-class method because Restricted Stock Awards ( RSAs ) include voting and dividend rights and are therefore participating shares.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
Strategy & priorities
About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists.
SEC original ↗Corcept Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
We classify inventory we do not expect to utilize within 12 months of the balance sheet date as strategic inventory, a non-current asset.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
We assess our potential liability in such situations by analyzing potential outcomes under various litigation, regulatory and settlement strategies.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
In December 2025, we exercised an expansion option (the Expansion Sublease ) with Zuora, Inc.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
The portion of the premises subject to the Expansion Sublease is 40,884 rentable square feet.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
Risks & headwinds
Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those expressed or implied by such statements.
SEC original ↗Corcept Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
These risks and uncertainties include, but are not limited to, those related to our ability to operate our business study and develop Korlym, relacorilant, miricorilant, dazucorilant and our other product candidates those molecules clinical attributes, regulatory approvals, mandates, oversight and other requirements and the scope and protective power of our intellectual property.
SEC original ↗Corcept Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
LEGAL PROCEEDINGS 27 ITEM 1A.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
We assess our potential liability in such situations by analyzing potential outcomes under various litigation, regulatory and settlement strategies.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
For further information about our ongoing legal matters, see Part II, Item 1, Legal Proceedings.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
For a complete discussion of such statements and the potential risks and uncertainties that may affect their accuracy, see the Risk Factors, Overview and Liquidity and Capital Resources sections of this Form 10-Q.
SEC original ↗Corcept Therapeutics Inc. — 10-Q Quarterly report10-QJul 29, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
34 documents- Q2 2026
- 8-KCORT
Sep 23, 2026
- 10-QCORT
- 8-KCORT
Jul 29, 2026
- Q1 2026
- 8-KCORT
Jun 17, 2026
- 8-KCORT
- 8-KCORT
May 28, 2026
- 10-QCORT
- 8-KCORT
Apr 30, 2026
- Q4 2025
- 8-KCORT
Mar 25, 2026
- EX-99CORT
Mar 25, 2026
- 10-KCORT
Feb 24, 2026
- 8-KCORT
Feb 24, 2026
- 8-KCORT
Feb 19, 2026
- EX-99CORT
Feb 19, 2026
- 8-KCORT
Jan 22, 2026
- EX-99CORT
Jan 22, 2026
- Q3 2025
- 8-KCORT
Dec 31, 2025
- EX-99CORT
Dec 31, 2025
- 10-QCORT
- 8-KCORT
- 8-KCORT
Oct 14, 2025
- 8-KCORT
- Q2 2025
- 8-KCORT
Sep 10, 2025
- 10-QCORT
- 8-KCORT
Jul 31, 2025
- 8-KCORT
Jul 14, 2025
- Q1 2025
- 8-KCORT
Jun 16, 2025
- 10-QCORT
- 8-KCORT
- Q4 2024
- 8-KCORT
Mar 31, 2025
- 8-KCORT
- 10-KCORT
Feb 26, 2025
- 8-KCORT
Feb 26, 2025
- Q3 2024
- 8-KCORT
Dec 30, 2024
Earnings releases
9 documentsPresentations
0 documentsNo presentations for Corcept Therapeutics Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Corcept Therapeutics Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.